Coumarin Derivatives as Anticancer Agents for Lung Cancer Therapy: A Review

Author(s): Manvendra Kumar, Ramit Singla, Jyoti Dandriyal, Vikas Jaitak*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 18 , Issue 7 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: The prevalence of lung cancer is 14% among the newly diagnosed cancer cases worldwide. Currently, the number of drugs that are in clinical practice is having a high prevalence of side effect and multidrug resistance. Researchers have made an attempt to expand a suitable anticancer drug that has no MDR and side effect.

Objective: Extensive exploration of Coumarin derivatives as a potent inhibitor of variety of proteins including EGFR, tyrosine kinase, ERK1/2, PI3K, HSP 90, Bax, STAT proteins, NF-κB and telomerase which have been associated with lung cancer.

Method: The recent literature was surveyed utilizing the online resources and databases including scifinder, pubchem, EMBL, scopus and google scholar.

Results: Upon analyzing the structure-activity relationship, it was found that N-aryl carboxamide, phenyl substitution at the C-3 position and 1,2,3- triazolyl, trihydroxystilbene, amino substitution at the C-4 position of the coumarin nucleus were the most effective in targeting lung cancer.

Conclusion: This review is a collaborative and extensive compilation of synthetic strategies, mechanism of action, and the structure-activity relationship thereof for the management of lung carcinoma.

Keywords: Lung cancer, MDR, coumarin, NSCLC, SCLC, multidrug resistance.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 30 November, 2018
Page: [964 - 984]
Pages: 21
DOI: 10.2174/1871520618666171229185926
Price: $65

Article Metrics

PDF: 41
HTML: 12